TORONTO, ONTARIO–(Marketwire – Dec. 7, 2012) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTCBB:FOIFF) today announced that Arch scientists have reported results of a recent study involving Arch peptides and the role they play in reducing initial biofilm formation and surface corrosion on stainless steel.
Press Releases
Dr. Julia Liu to Present at American College of Gastroenterology Annual Meeting Oct 22, 2012
TORONTO, ONTARIO–(Marketwire – Oct. 18, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that Dr. Julia Liu will be presenting new data on the topic “Confocal Laser Endomicroscopy Findings of the Small Intestine in Irritable Bowel Syndrome (IBS) patients” at the American College of Gastroenterology’s (ACG) Annual Scientific Meeting in Las Vegas, October 19-24.
Arch Biopartners Enters Option to Acquire Irritable Bowel Syndrome Diagnostic Technology
TORONTO, ONTARIO–(Marketwire – Sept. 6, 2012) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTCBB:FOIFF) announces it has entered into an option agreement to acquire the intellectual property rights to a new diagnostic technology which identifies irritable bowel syndrome (IBS).
Arch Scientists Successfully Image Brain Tumour Initiating Cells Using MRI
TORONTO, ONTARIO–(Marketwire – Aug. 21, 2012) – Arch Biopartners Inc (“Arch”) (CNSX:ACH)(OTCBB:FOIFF) today announced Arch scientists have successfully used magnetic resonance imaging (“MRI”) to detect human brain tumour initiating cells in mice using Arch’s proprietary cell targeting technology.
Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology
TORONTO, CANADA–(Marketwire – March 15, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research Council of Canada – Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch in the development of diagnostic imaging applications for its brain tumour initiating cell (“BTIC”) targeting technology.
Arch Scientists to Lead Anti Corrosion Project for Auto Industry
TORONTO, ONTARIO–(Marketwire – Feb. 28, 2012) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) today announced that AUTO21 and its contributing partners have approved funding totaling $518,400 for Arch scientists to lead an anti corrosion project on Magnesium (“Mg”) and rare earth (“RE”) alloys for the Canadian auto industry.
Arch Biopartners Appoints Claude Allary as Special Advisor
TORONTO, ONTARIO–(Marketwire – Jan. 24, 2012) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) announced today Claude Allary has been appointed Special Advisor to the Company. In this capacity, Mr. Allary will provide expertise in evaluating commercial opportunities for the Company’s drug development platforms and other emerging technologies.
Arch Scientists Inhibit Biofilm Formation and Increase Hardness on Titantium
TORONTO, ONTARIO–(Marketwire – Dec. 19, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists have inhibited biofilm formation on titanium using the Company’s proprietary peptide technology.
Arch Biopartners Engages Intertek Cantox to Devise Drug Development Plan for Lead Cancer Compound
TORONTO, ONTARIO–(Marketwire – Nov. 7, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced it has engaged Intertek Cantox (“Cantox”) to devise the drug development plan for the Company’s lead compound, GH501a.
Arch Biopartners Identify Lead Compound for Pancreatic Cancer and Non Small Cell Lung Cancer
TORONTO, ONTARIO–(Marketwire – Sept. 7, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) today announced it has identified a lead compound, named GH501a, for further development as potential treatment for non small cell lung cancer and pancreatic cancer.